EpiBone’s pioneering technology uses a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a bone graft with the precise anatomical fit to the defect being treated. EpiBone will offer surgeons simplified procedures and patients improved bone formation and regeneration, with shorter recovery times, without the complications of synthetic implants.
Based on 15 years of NIH-funded bone tissue engineering research, EpiBone’s technology was developed by Columbia Professor Gordana Vunjak-Novakovic. The company is led by CEO, Nina Tandon, a former post-doctoral fellow in the Vunjak-Novakoic laboratory and Senior TED Fellow.
Therapeutics – Regenerative Medicine
Nina Tandon, CEO
New York, NY, US